BetterMe Rx vs ShedRx
Two GLP-1 desks, one scoreboard. We put BetterMe Rx and ShedRx head-to-head on the published Brief Score — the same six factors, scored the same way.
ShedRx
The verdict
ShedRx takes this head-to-head.
ShedRx scores 87 to 85 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.
That doesn't make BetterMe Rx a bad call — it's best for readers who want an accredited desk with an oral route and don't need the rock-bottom price. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| BetterMe Rx | ShedRx | |
|---|---|---|
| Brief Score | 85/100 (B) | 87/100 (B+) |
| Semaglutide | $199/mo | $199/mo |
| Tirzepatide | $299/mo | $299/mo |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Fallingprice falling |
BetterMe Rx: $199 sema / $299 tirz held at the mid-market line; LegitScript-certified.
ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.